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Abstract
Background and Aims Adrenomedullin (AM) is a multi-
functional biologically active peptide that has an amelio-
rative effect against inflammatory bowel disease in several
experimental models. We reported the first case where AM
infusion dramatically improved symptoms and colono-
scopy findings in patients with refractory ulcerative colitis
(UC). To confirm the reproducibility of the efficacy and
safety of AM infusion, this pilot study evaluated the clin-
ical feasibility of intravenous administration of AM in
patients with refractory UC.
Methods Seven patients with active refractory UC par-
ticipated and received intravenous infusion of AM
(1.5 pmol/kg/min) for 8 h daily for 14 days, and their
Disease Activity Index (DAI) were evaluated before and 2
and 12 weeks after beginning AM administration.
Results DAI were improved in all patients after AM
administration. Within 2 weeks, marked declines in DAI
(C3 points and C30 %) were observed in six patients
(85.7 %), while a more modest decline was observed in
one patient (14.3 %). Overall mean DAI improved from
9.3 ± 0.6 at baseline to 4.6 ± 0.8 at 2 weeks, and then to
1.2 ± 0.5 at 12 weeks. Endoscopic examination revealed
substantial amelioration of ulcers, with mucosal healing
and scarring. Four patients remained in clinical remission
12 months after AM treatment. AM administration pro-
duced significant increases in plasma AM concentrations
(approximately 2.5-fold) that had a mild effect on blood
pressure and heart rate, but with no serious adverse effects.
Conclusion AM is a potentially useful agent that acts via
a novel mechanism to safely induce mucosal healing and
clinical remission in patients with refractory UC.
Keywords Ulcerative colitis  Adrenomedullin 
Biologically active peptide  Clinical pilot study  Mucosal
healing
Introduction
Adrenomedullin (AM) is a biologically active peptide first
isolated from human pheochromocytoma based on its
potent vasodilatory activity [1]. AM is ubiquitously dis-
tributed in the body and exerts a wide range of physio-
logical effects in addition to vasodilation, including
cardiovascular protection, neovascularization, and sup-
pression of inflammation and apoptosis [2–4]. Moreover,
evidence from several studies suggests that AM might be
effective clinically as a therapeutic agent for the treatment
of cardiovascular diseases such as acute myocardial
infarction, heart failure, hypertension, pulmonary hyper-
tension, and limb ischemia [5–8].
AM immunoreactivity has been detected throughout the
gastrointestinal tract, with especially high concentrations in
the stomach and colon [2]. We previously reported that AM
had an ameliorative effect in two experimental colitis
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models, acetic acid-induced colon ulcer, and dextran sul-
fate sodium-induced colitis [9, 10]. We further showed that
the mechanism of the effect of AM likely involved sup-
pressing the activity of inflammatory cytokines, activating
regulatory cytokines in intestinal intra-epithelial lympho-
cytes, protecting intercellular junctions and exerting
antibacterial effects [9]. In addition, AM reportedly exerts
beneficial effects on microvascular function and con-
tributes to the re-epithelialization of ulcers in experimental
models of colitis [11–13]. Collectively, these findings
suggest AM might be an effective agent for the treatment
of UC, exerting anti-inflammatory and antibacterial effects
and stimulating mucosal regeneration and maintenance of
the colonic epithelial barrier.
In addition to experimental models of inflammatory
bowel disease (IBD), we previously reported the first case
where AM infusion dramatically improved symptoms and
colonoscopy findings in patients with refractory UC [14].
To confirm the reproducibility of the efficacy and safety of
AM infusion, this pilot study evaluated the clinical feasi-




The present study was a single-center, prospective, non-
randomized clinical study performed between July 2010
and June 2013.
Patient Selection
Eligible patients included males and females who were at
least 20 years of age and who had been diagnosed with UC
according to the standard criteria for symptoms and stan-
dard radiographic and endoscopic criteria. Included in the
study were: (1) patients who had moderate-to-severe active
UC uncontrollable with 5-aminosalicylic acid (5-ASA)
and/or corticosteroid therapy and who could not use cal-
cineurin inhibitors or biological agents for any reason; (2)
intractable patients exhibiting steroid resistance; and (3)
intractable patients exhibiting steroid dependency. The
definitions of steroid resistance and steroid dependency
were based on the guidelines for the management of
ulcerative colitis in Japan [15]. Steroid resistance was
defined as unresponsiveness to an appropriate dose of
corticosteroid (a daily dose of 40 mg or more of pred-
nisolone) over at least 7 days. Steroid-dependent patients
were defined as those with active UC and who are unable to
reduce or be weaned from steroid therapy. Patients were
evaluated using the Disease Activity Index (DAI) [16]. As
an entry criterion, patients were required to have a total
DAI of 6 or higher and a mucosal appearance subscore of 2
or 3.
The exclusion criteria were pregnancy or lactation, ful-
minant severe UC, a history of malignancy or sign of
dysplasia, a history of coronary artery disease or cere-
brovascular disease, severe liver or kidney dysfunction, or
a history of active infection.
Preparation of Human AM
We prepared human AM as previously described [17].
Briefly, the peptide was chemically synthesized in accor-
dance with current good manufacturing practices (CGMP)
at Peptide Institute, Inc, Osaka, Japan. The chemical nature
of the peptide and the detailed contents of the vials were
verified using reverse-phase high-performance liquid
chromatography and amino acid analysis. No measurable
endotoxin was detected (\0.01563 EU ml-1), and the
material was determined to be pyrogen free by the Japan
Food Research Laboratories (Tokyo, Japan). For infusion,
AM was dissolved in distilled water with 3.75 % D-man-
nitol, after which the solution was sterilized by passage
through a 0.22-lm filter (Millipore, Co, Billerica, MA).
Treatment
AM was intravenously administrated for 8 h at a rate of
1.5 pmol/kg/min (9 ng/kg/min) daily for 14 days. If a
patient’s symptoms worsened at any time, and the inves-
tigator decided the study drug could not be continued, the
treatment was considered a failure.
Concomitant Medications
While receiving AM, patients were allowed to continue
taking drugs containing 5-ASA as long as the dosage of
those drugs was not altered during the period starting
2 weeks prior to the beginning of the study. For steroids,
the dosage had to remain unchanged during the period of
AM administration. The initial steroid dose was
60 mg/day, and it was reduced to 40 mg/day after 2 weeks.
Subsequently, the steroid dose was tapered to 5 mg
biweekly. The steroid dosage was maintained for the initial
2 weeks in patients who received a dose of prednisolone of
40 mg/day or less. However, patients who were adminis-
tered a dose of prednisolone C60 mg/day were permitted to
decrease their dosage during the AM therapy period.
Patients who began taking azathioprine or tacrolimus less
with 3 months prior to this study were excluded. Patients
who began taking azathioprine more than 3 months prior to
the start of this study were permitted to continue taking the
drug at the same dosage. Treatment with tacrolimus,
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cyclosporine, or infliximab could not be initiated during the
study.
Study Endpoints
The primary endpoint of this study was a clinical response
evaluated based on the DAI following the administration of
AM. A clinical response was defined as a reduction in total
DAI from baseline of at least 3 points and at least 30 %,
with an accompanying reduction in the subscore for rectal
bleeding of at least 1 point or an absolute subscore for
rectal bleeding of 0 or 1. DAI subscores, including endo-
scopic assessment, were determined within 1 week before
AM infusion, 2 weeks after initiating infusion, and then at
week 12 after initiating infusion. Secondary endpoints
included: clinical remission (defined as a total DAI of 2
points or lower, with no individual subscore exceeding 1
point); endoscopic findings showing mucosal healing (de-
fined as an absolute subscore for endoscopy of 0 or 1); a
hemodynamic response to AM administration (tolerabil-
ity); a difference in the plasma AM concentration before
and after AM administration; and the biochemical mea-
surements described below.
Blood Chemistry
Plasma levels of mature AM were measured using a
specific immunoassay kit (Shionogi, Osaka, Japan) [18].
Routine hematology and blood chemistry analysis were
performed before infusion and 4, 8, and 24 h after the start
of infusion. At the same time, plasma concentrations of
high-sensitivity C-reactive protein, interleukin-4, inter-
leukin-6, interferon-c, tumor necrosis factor-a, and trans-
forming growth factor-1b were measured using a
commercial laboratory testing service (SRL, Hachioji,
Japan).
Statistical Analysis
Statistical analysis was performed using Statview 5.0 (SAS
Institute Inc, Cary, NC, USA). The statistical significance
of any difference between means was evaluated using a
paired t test. Values of p\ 0.05 were considered statisti-
cally significant.
All authors had access to the study data and had
reviewed and approved the final manuscript.
Ethical Considerations
This study was conducted in a manner conforming to the
ethical principles of the Declaration of Helsinki. Before
beginning this study, we obtained approval from the
institutional review board at the participating medical
institution. This study was registered with the University
Hospital Medical Information Network (UMIN) Clinical




We enrolled seven patients with moderate-to-severe active
UC that was refractory to conventional combination ther-
apy. The mean age of the patients was 55.1 ± 10.4 years
(mean ± SD; range 37–68 years). The clinical back-
grounds of the patients enrolled in this study are summa-
rized in Table 1. Endoscopies performed before the study
revealed four patients had left-sided colitis and three had
total colitis. All seven patients had first been treated with
5-ASA, while 6 also received steroid therapy and 2 had
tried cytapheresis (Table 1). All seven patients were
refractory to 5-ASA, and 6 of the 7 patients had steroid-
refractory ulcerative colitis. Patient 4 was classified as
having steroid-dependent colitis, but the steroid therapy
had been discontinued because of a history of excessive
steroid dosage. The mean DAI for patients at admission
was 10.9 ± 0.4 (mean ± SEM; range 9–12), and the initial
therapies did not substantially improve the clinical findings
(Table 1). The mean DAI at baseline was 9.3 ± 0.6
(p = 0. 0914 vs. score at admission).
No patient received a calcineurin inhibitor (cyclosporine
or tacrolimus) or a biologic (infliximab or adalimumab) if
they had a history of tuberculosis or were in an immuno-
compromised state. One patient (patient 3) refused




A clinical response at week 2, as reflected by the DAI
score, was observed in six patients (85.7 %), while one
patient (patient 6) (14.3 %) showed a partial response. The
mean DAI for all patients significantly improved from
9.3 ± 0.6 at baseline to 4.6 ± 0.8 2 weeks after initiating
AM treatment (p\ 0.001) (Fig. 1; Table 2). Although
patient 4 showed a significant response (reduction of 3
points and 33.3 % from baseline), she failed to induce
remission. She required infliximab therapy soon after AM
therapy, but that was clinically and endoscopically inef-
fective. Patient 6 showed a partial response (reduction of 3
points and 27.3 % from baseline), but underwent remission
after AM therapy. However, she had a total colectomy to
874 Dig Dis Sci (2016) 61:872–880
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prevent recurrence according to patient’s desire. The other
five patients progressed favorably, and their DAI improved
to 1.2 ± 0.5 within 12 weeks after initiating treatment
(Fig. 1; Table 2). A clinical remission with mucosal
healing was observed in one patient (14.3 %) at week 2
and in five patients (71.4 %) at week 12.
In three of four patients examined 1 year after AM
treatment (patients 1, 2, and 3), the mucosa of the colon
remained in remission without steroid therapy (Table 2).
Patient 1 in the present study (Tables 1, 2) was reported
previously in a case report [14].
Endoscopic Findings
All seven patients were evaluated endoscopically on
admission and just before and after AM treatment. Before
AM therapy, all seven patients exhibited active inflam-
matory lesions with diffuse edema, loss of the usual fine
vascular pattern, granularity, and easy mucosal bleeding.
Furthermore, in six of the patients, wide, deep ulcers were
observed in the colon. After 2 weeks of AM therapy,
endoscopy showed a reduction in inflammation in all
patients, and significant neovascularization and mucosal
regeneration were observed at the margins and base of the
deep ulcers in those patients who had ulcerative lesions. Of
note, remarkable fibroses (scarring) were seen in the
remaining relatively shallow ulcers, and scarred regions
had a reticulated appearance (Fig. 2). At 12 weeks after
initiating AM treatment, these ulcers had disappeared and
only clean scars remained (Fig. 2).
Plasma AM Concentration and Serum Biomarkers
Figure 3a shows time-dependent changes in the plasma
levels of mature AM during and after AM infusion. The
Fig. 1 Clinical effectiveness of AM. Total DAI score measured at
baseline (prior) and 2 weeks after (2 W) and 12 weeks after (12 W)
initiating AM administration in seven patients. Values are the
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data from patient 4 were omitted because her plasma AM
level increased to about 250 fmol/ml ([160 times greater
than baseline) on transfusion day 1 and was considered
aberrant, as it could not be accounted for by the low dose of
exogenous AM administered. Among the remaining six
patients, AM levels were unchanged on the day before AM
administration, but AM administration produced significant
increases in mature AM (approximately 2.5-fold). After
stopping AM infusion, plasma AM levels declined to
baseline levels by the next morning.
Serum interleukin-6 and tumor necrosis factor-a levels
tended to be lower after 8 h of AM infusion than before
infusion (interleukin-6: 12.0 ± 14.1 vs. 6.6 ± 9.0 pg/ml,
p = 0.069; tumor necrosis factor-a: 1.5 ± 0.8 vs.
1.2 ± 0.7 pg/ml, p = 0.17). AM infusion was not associ-
ated with a change in any other serum biomarkers (high-
sensitivity C-reactive protein, interleukin-4, interferon-c,
and transforming growth factor-1b; data not shown).
Safety
AM therapy was generally well tolerated by all seven
patients. No severe adverse events were observed during
or after AM infusion (Table 3). Patient 4 developed a
transient high fever about 4 h after completion of the
first AM administration that declined in one night,
which was suspected of being caused by a temporary
infection.
Changes in blood pressure and heart rate during AM
infusion are shown in Fig. 3b. The primary biological
effects of AM are a reduction in blood pressure and an
increase in heart rate, but these effects were mild in our
patients and did not cause clinical symptoms such as
fainting or headache. Blood pressure and heart rate
returned to their baseline levels soon after the AM infusion
finished. Additionally, no significant liver or renal dys-
function was observed during or after AM administration.
Discussion
We evaluated the safety and efficacy of exogenous AM
administered to patients with intractable UC in a prelimi-
nary open-label exploratory clinical study. Although the
number of patients enrolled was small, AM therapy might
be useful to ameliorate otherwise intractable UC, as it
stimulated mucosal regeneration accompanied by neovas-
cularization and vasodilation visible by endoscopic exam-
ination, without significant adverse effects. We previously
reported the first case where AM infusion dramatically
improved symptoms and colonoscopy findings in patients
with refractory UC [14]. The present clinical study clearly
shows the reproducibility of AM therapy in intractable UC.
In the present study, all patients experienced some
improvement of their clinical symptoms with the admin-
istration of AM, and over 80 % (6 of 7) showed a clinical
response in DAI within 2 weeks (Table 2). Patients 4 and 6
did not achieve a full clinical response; however, patient 6
showed favorable remission but underwent a total colec-
tomy to prevent recurrence in accordance with her wishes.
It is noteworthy that the endoscopic findings of patient 4
showed diffuse edematous and coarse granular mucosa
without distinct ulcers, which are target of AM therapy.
Although the mechanisms of action of AM against
colitis is still unclear, earlier observations by others and
ourselves using experimental colitis models suggest several
possible mechanisms [9–13, 19]. AM exerts beneficial
effects against experimental colitis by regulating inflam-
matory responses, for example, the suppression of systemic
and local production of inflammatory cytokines. It was also
shown that AM contributed to mucosal protection and
regeneration, the re-epithelialization of injured mucosal
tissue, and the maintenance of epithelial intercellular
junctions [9]. In addition, AM stimulated angiogenesis and
improved microcirculation and mucosal permeability [9].
In the present study, endoscopic findings showed signifi-
cant regeneration of the mucosa with scarring and marked
Table 2 Clinical effectiveness of AM: changes in total DAI score and DAI subscores
Patient no. Total UC-DAI Frequency score Bleeding score Endoscopic score Investigator’s global assessment
Prior 2 W 12 W Prior 2 W 12 W Prior 2 W 12 W Prior 2 W 12 W Prior 2 W 12 W
1 7 2 0 1 0 0 1 0 0 2 1 0 3 1 0
2 11 6 2 2 1 0 3 1 0 3 2 1 3 2 1
3 10 3 2 3 1 0 1 0 0 3 1 1 3 1 1
4 9 6 F 3 1 F 2 1 F 2 2 F 2 2 F
5 8 4 2 1 0 0 1 0 0 3 2 1 3 2 1
6 11 8 F 3 3 F 3 1 F 2 2 F 3 2 F
7 9 3 0 2 1 0 1 0 0 3 1 0 3 1 0
F failure
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angiogenesis, suggesting mucosal healing. AM thus
appears to have multiple beneficial effects against colitis,
suggesting its therapeutic mechanism may be complex.
In the acetic acid-induced colonic ulcer model [10], a
solitary ulcer is induced by the subserosal injection of acetic
acid into the colon. Thus, ulceration is the result of a chemical
injury rather than an immunological disorder, such as that seen
in the dextran sulfate sodium-or 2,4,6-trinitrobenzenesulfonic
acid-induced colitis models. AM was effective in all three
models, which is consistent with the idea that it acts not only
by inhibiting the production of inflammatory cytokines, but
also by stimulating tissue reconstruction through re-epithe-
lialization and vascularization.
Following the development of biologics, which are highly
effective for the treatment of IBD, mucosal healing by endo-
scopy is considered an important indicator of efficacy, and
mucosal healing with the extinction of acute inflammation is
now established as the therapeutic goal in IBD [20]. Collec-
tively, ourfindings suggest that in patientswith colitis,AMmay
exert both anti-inflammatory effects and effects contributing to
mucosal regenerationwith vascularization, which indicate AM
is a potential candidate for use in the treatment of IBD.
Because AM is a biologically active peptide with potent
hypotensive activity, continuous intravenous infusion of
AM should be employed. We used a relatively low dose of
AM (1.5 pmol/kg/min), and it was infused for only 8 h daily
Fig. 2 Colonoscopic findings. Colonoscopic findings in patients 2, 3,
6, and 7 (representative cases) are shown. Wide and deep ulcers,
edema, and erythema were observed in the colon before AM therapy
(left panels). Following AM therapy (middle panels), mucosal edema,
and erythema were decreased, and significant mucosal regeneration
was observed. In patient 7, ulcer scarring was seen. Twelve weeks
after initiating AM treatment (right panels), the ulcers had disap-
peared and ulcer scars were observed. The colonoscopic examination
of patient 6 at week 12 was not performed, because she had a total
colectomy to prevent recurrence according to her request
Dig Dis Sci (2016) 61:872–880 877
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for 14 days. We previously characterized the hemodynamic
and hormonal effects of exogenous AM in humans and
showed that prolonged administration elicited a strong and
steady reduction in blood pressure with significant increases
in the plasma AM concentration [17, 21]. In patients with
essential hypertension, for example, continuous AM infu-
sion at 2.5 pmol/kg/min (15 ng/kg/min) for 27 h safely
caused a significant reduction in blood pressure. Kataoka
et al. [6] reported a pilot study examining the effects of
intravenous AM administration in patients with acute
myocardial infarction. They found that AM infusion at
12.5–25 ng/kg/min for 12 h significantly improved cardiac
wall motion in the infarct area, while the hemodynamic
parameters remained nearly unchanged. We selected an AM
dose of 1.5 pmol/kg/min (9 ng/kg/min) for 8 h, which pro-
duced about a 2.5-fold increase in plasma AM levels during
infusion (Fig. 3a). Thiswas accompanied bymild changes in
blood pressure and heart rate with no adverse effects such as
headache or fainting (Fig. 3b). Although the most serious
side effect of AM is hypotension, the present study demon-
strated the safety of intravenousAM infusion in patientswith
refractory ulcerative colitis in regard to the threat of devel-
oping hypotension.
The therapeutic effects of AM against experimental col-
itis [12, 13, 22] and gastritis [23] exhibited a bell-shaped
dose–response; that is, the beneficial effects ofAM increased
as the dose increased until a peak was reached, after which
the benefits were reduced as the dose was increased further.
Thus, although the AM dose used in this study showed both
efficacy and safety, the optimal dose remains unknown.
Patients suitable for AM therapy are limited because
they must stay in hospital for more than 2 weeks. We
mainly enrolled patients with moderate-to-severe refrac-
tory UC who were unable to take anything by mouth.
Furthermore, patients enrolled in the present study were
unable to receive immunosuppressants or biologics because
of concern about their age and/or underlying diseases,
which included impaired glucose tolerance, renal insuffi-
ciency, cardiovascular disease, and past tuberculosis.
It was shown in patients with intractable moderate-
to-severe active UC that a poor response to high-dose steroid
therapy is often treatable with immunosuppressants (e.g.,
Fig. 3 Effect of AM infusion on plasma AM levels. a Plasma AM
levels. Symbols depict mean ± SEM. AM infusion was initiated at
0 h and continued for 8 h (horizontal bar at top). *p\ 0.05;
**p\ 0.01 versus baseline. b Blood pressure and pulse rate. Effect
of AM infusion on blood pressure and pulse rate. Symbols depict
mean ± SEM. AM infusion was initiated at 0 h and was continued
for 8 h (horizontal bar at top). Filled circles systolic blood pressure,
filled triangles diastolic blood pressure, open diamonds heart rate.
*p\ 0.05 versus baseline
Table 3 Clinical outcome of each patient
Patient no. Efficacy at 2 W PSL tapering (mg/day) Long-term (1 Y) outcome Adverse events
Prior at 24 W
1 Yes 25 5 In remission at 1 Y None
2 Yes 40 3 In remission at 1 Y None
3 Yes 60 2.5 In remission at 1 Y None
4 Yes 0 – Resistance to IFX Transient high fever
5 Yes 60 0 Relapse after 9 M None
6 No 40 – Colectomy after induction of remission with AM None
7 Yes 30 5 Relapse after 12 M None
Y year, M month, W week, PSL prednisolone, IFX infliximab, AM adrenomedullin
878 Dig Dis Sci (2016) 61:872–880
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cyclosporine or tacrolimus) or biologics (e.g., infliximab or
adalimumab) [24]. Although they are generally effective, a
considerable number of patients respond poorly to these
agents, or the drugs show a progressive loss of efficacy [25].
Because AM is an endogenous biologically active peptide in
human, antibodies against AM administered should not be
produced. Therefore, AM might form the basis of a safe
medicinal drug without anaphylactic reaction or progressive
loss of efficacy.
The limitations of this study include its open-label,
nonrandomized, single-arm, single-dose design, its small
sample size, and the possible subjectivity of the DAI
scoring. In addition, because of the strict inclusion criteria,
only a small number of patients were eligible for this study,
which was a limitation of this single-center clinical study.
In summary, we have shown that continuous intravenous
infusion of AM at a dose of 1.5 pmol/kg/min (9 ng/kg/min)
produced beneficial effects that ameliorated the symptoms
of intractable UC without adverse side effects. Moreover,
endoscopic evaluation after AM therapy revealed remark-
able mucosal regeneration and healing with neovascular-
ization at previously ulcerative or erosive lesions. These
results suggest AM is a potentially useful therapeutic agent
with a novel mechanism of action involving anti-inflam-
matory effects with mucosal and vascular regeneration. We
are now preparing for an investigator initiated clinical trial
of an AM formulation to develop a therapeutic pharma-
ceutical product for refractory UC.
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